Journal
JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE
Volume 10, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/jcdd10040135
Keywords
cancer; acute coronary syndrome (ACS); percutaneous coronary intervention (PCI); dual antiplatelet therapy (DAPT); triple antithrombotic therapy (TAT); atrial fibrillation (AF); cardiotoxicity
Categories
Ask authors/readers for more resources
Cardiovascular events in cancer patients can be caused by various factors, including risk factors, cancer itself, and anticancer therapy. Administering dual antiplatelet therapy (DAPT) to cancer patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) is a challenge to cardiologists. This review aims to explore the optimal antiplatelet therapy and duration of DAPT in order to reduce ischemic and bleeding risk in this high-risk population.
Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac diseases, such as PAD and CVAs, may require DAPT. The aim of the present review is to review the current literature on the optimal antiplatelet therapy and duration of DAPT for oncologic patients, in order to reduce both the ischemic and bleeding risk in this high-risk population.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available